Citations

Showing 10 of 108081 citations.

Patient Safety Interprofessional Training for Medical, Nursing, and Pharmacy Students
Gill, Anne C. , Cowart, Jennifer B. , Hatfield, Catherine L. , Stritto, Rita Ann Dello, Landrum, Peggy, Ismail, Nadia , Nelson, Elizabeth A., Teal, Cayla R. , Nelson, Elizabeth A.

Mayo Clinic

MedEdPORTAL | June 15, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.10595 | PMID 30800797 Get It

Loss of FAM46C Promotes Cell Survival in Myeloma
Zhu, Yuan Xiao , Shi, Chang-Xin, Bruins, Laura A., Jedlowski, Patrick , Wang, Xuewei , Luo, Moulun , Ahmann, Jonathan M., Braggio, Esteban , Stewart, A. Keith, Kortüm, K. Martin , Braggio, Esteban

Mayo Clinic

Cancer Research | June 15, 2017 | Volume: 77 | Issue: 16 | Pages: 4317-4327

10.1158/0008-5472.can-16-3011 | PMID 28619709 Get It

Abstract FAM46C is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that wild-type (WT) FAM46C overexpression induces substantial cytotoxicity in multiple myeloma cells. In contrast, FAM46C mutations found in multiple myeloma patients abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP. Furthermore, pathway analysis suggests that enforced FAM46C expression activated the unfolded protein response pathway and induced mitochondrial dysfunction. CRISPR-mediated depletion of endogenous FAM46C enhanced multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and antiapoptotic signaling, and conferred relative resistance to dexamethasone and lenalidomide treatments. Genes altered in FAM46C-depleted cells were enriched for signaling pathways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling. Together these results implicate FAM46C in myeloma cell growth and survival and identify FAM46C mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis. Cancer Res; 77(16); 4317–27. ©2017 AACR.
Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?—Reply
Shi, Qian , Sinicrope, Frank A. , Alberts, Steven R. , Shi, Qian

Mayo Clinic

JAMA Oncology | June 15, 2017 | Volume: 3 | Issue: 9 | Pages: 1285

10.1001/jamaoncol.2017.1474 | PMID 28617912 Get It

Immigration, Graduate Medical Education, and Ethical Dilemmas
Bdair, Fadi, Murad, M. Hassan , Wooldridge, David , Mustafa, Reem A , Murad, M Hassan

Mayo Clinic

Journal of Graduate Medical Education | June 15, 2017 | Volume: 9 | Issue: 3 | Pages: 280-282

10.4300/jgme-d-17-00124.1 | PMID 28638502 Get It

Modern reirradiation for recurrent gliomas can safely delay tumor progression
Youland, Ryan S. , Lee, John , Kreofsky, C.R., Brown, Paul D. , Uhm, Joon H. , Lee, John Y, Kreofsky, Cole R, Laack, Nadia N.

Mayo Clinic

Neuro-Oncology Practice | June 15, 2017 | Volume: 5 | Issue: 1 | Pages: 46-55

10.1093/nop/npx014 | PMID 31385961 Get It

Abstract Background Despite advances in modern therapy, high-grade gliomas continue to portend a dismal prognosis and nearly all patients will experience relapse. Unfortunately, salvage options remain limited. In this study, we assessed outcomes for patients with recurrent gliomas treated with reirradiation. Methods We retrospectively identified 48 glioma patients treated with reirradiation between 2013 and 2016. All had radiographic or pathologic evidence of recurrence. Prognostic factors were abstracted from the electronic medical record. Results Initial surgery included biopsy in 15, subtotal resection in 21, and gross total resection in 12. Initial chemotherapy included temozolomide (TMZ) in 31, TMZ+dasatinib in 7, TMZ+vorinostat in 3, and procarbazine, lomustine, and vincristine in 2. The median dose of primary radiotherapy was 60 Gy delivered in 30 fractions. Median overall survival (OS) and progression-free survival (PFS) from initial diagnosis were 3.2 and 1.7 years, respectively. A total of 36 patients failed salvage bevacizumab before reirradiation. Salvage surgery was performed before reirradiation in 21 patients. Median time to reirradiation was 1.7 years. Median follow-up was 13.7 months from reirradiation. Concurrent systemic therapy was given in 33 patients (bevacizumab in 27, TMZ in 8, and lomustine in 2). Median PFS and OS after reirradiation were 3.2 and 6.3 months, respectively. Radionecrosis occurred in 4 patients and no radionecrosis was seen in patients receiving concurrent bevacizumab with reirradiation (0% vs 19%, P = .03). Conclusions Reirradiation may result in delayed tumor progression with acceptable toxicity. Prospective trials are needed to determine the impact of reirradiation on tumor progression and quality of life.
Epilepsy and mortality after aneurysmal subarachnoid hemorrhage
Harroud, Adil , Crepeau, Amy Z.

Mayo Clinic

Neurology | June 15, 2017 | Volume: 89 | Issue: 3 | Pages: 222-223

10.1212/wnl.0000000000004125 | PMID 28615424 Get It

Physiology in Perspective: Structure and Function—Anatomy and Physiology Are Integral
Sieck, Gary C.

Mayo Clinic

Physiology | June 15, 2017 | Volume: 32 | Issue: 4 | Pages: 264-265

10.1152/physiol.00014.2017 | PMID 28615310 Get It

Long‐term follow‐up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non‐Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) M
Witzig, Thomas E. , Johnston, Patrick B. , LaPlant, Betsy, Kurtin, Paul J. , Pederson, Levi , Moore, Dennis F., Nabbout, Nassim H., Nikcevich, Daniel A., Rowland, Kendrith M. , LaPlant, Betsy R, Pederson, Levi D , Witzig, T.E. , Grothey, Axel

Mayo Clinic

American Journal of Hematology | June 14, 2017 | Volume: 92 | Issue: 10 | Pages: 1004-1010

10.1002/ajh.24824 | PMID 28614905 Get It

AbstractPatients with relapsed aggressive non‐Hodgkin lymphoma (NHL) are often treated with platinum‐based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m2 IV weekly x 4 doses (cycle 1 only); dexamethasone 40 mg PO/IV d2 – 5; oxaliplatin 130 mg/m2 IV day 2; cytarabine 2000 mg/m2 IV × two doses on days 2 to 3; and pegfilgrastim 6 mg SC on day 4. Forty‐five eligible patients were accrued between 2006 and 2008. Patient characteristics were a median age of 69 years; 96% had received prior rituximab; 53% were within one year of diagnosis. The median number of cycles received was 2 (range, 1‐6). Forty‐four % received ROAD as an outpatient. The overall response rate was 71% with 27% (12/45) CR and 44% (20/45) PR. Forty‐four % (20/45) of all patients and 69% (18/26) of patients whom responded after 2 cycles proceeded to transplant. Median overall survival was 26 mos (95% CI: 7.3 mos—not reached) and median progression‐free survival was 11 mos (95% CI: 6—104 mos). There was no grade 3/4 nephrotoxicity; the rate of grade 3/4 neuropathy was 4%. Forty‐two percent of all patients and 69% of patients transplanted remain alive at 5 years. ROAD represents an acceptable salvage therapeutic option for patients with relapsed aggressive NHL.
Identification of an Alu element‐mediated deletion in the promoter region of GNE in siblings with
Garland, Jennifer, Stephen, Joshi, Class, Bradley, Gruber, Angela , Ciccone, Carla, Poliak, Aarón , Hayes, Christina, Singhal, Vandana, Slota, Christina , Perreault, John, Gavrilova, Ralitza, Shrader, Joseph A. , Joe, Galen O., Heiss, John D. , Gahl, William A. , Huizing, Marjan , Carrillo, Nuria , Malicdan, May Christine V. , Malicdan, May Christine V , Chittiboina, Prashant

Mayo Clinic

Molecular Genetics & Genomic Medicine | June 14, 2017 | Volume: 5 | Issue: 4 | Pages: 410-417

10.1002/mgg3.300 | PMID 28717665 Get It

Abstract Background GNE myopathy is a rare genetic disease characterized by progressive muscle atrophy and weakness. It is caused by biallelic mutations in the GNE gene that encodes for the bifunctional enzyme, uridine diphosphate ( UDP )‐N‐acetylglucosamine (Glc NA c) 2‐epimerase/N‐acetylmannosamine (Man NA c) kinase. Typical characteristics of GNE myopathy include progressive myopathy, first involving anterior tibialis muscle and sparing the quadriceps, and rimmed vacuoles on muscle biopsy. Identifying biallelic mutations by sequencing of the GNE gene confirms the diagnosis of GNE myopathy. In a subset of patients, diagnostic confirmation is challenged by the identification of mutations in only one allele, suggesting mutations in deep intronic regions or regulatory regions. Methods We performed targeted sequencing and copy number variant ( CNV ) analysis of GNE in two siblings who clinically presented with GNE myopathy. Further molecular and biochemical studies were done to characterize the effect of a previously uncharacterized GNE mutation. Results We report two siblings of Indian descent with characteristic features of GNE myopathy, including progressive skeletal muscle weakness initially involving the anterior tibialis, and rimmed vacuoles on muscle biopsy, in which a heterozygous mutation, p.Val727Met, was identified in both affected siblings, but no other deleterious variants in either coding region or exon–intron boundaries of the gene. Subsequent insertion/deletion analysis identified a novel 11.3‐kb deletion (Chr9 [ GRC h37]: g.36257583_36268910del) encompassing the GNE promoter region, with breakpoints residing in Alu repeats. Gene expression analysis revealed reduced GNE mRNA and protein levels, confirming decreased expression of the deleted allele harboring the deletion. Conclusions We have identified GNE as one of the genes susceptible to Alu ‐mediated recombination. Our findings suggest that the deletion may encompass the promoter or another region necessary for GNE expression. In patients with typical manifestations of GNE myopathy and a single GNE variant identified, copy number variant ( CNV ) analysis may be useful in arriving at the diagnosis.
Porous Tantalum Femoral Metaphyseal Cones for Large Femoral Bone Defects in Revision Total Knee Arthroplasty
Nikolaus, O. Brant, Hanssen, Arlen D. , Lewallen, David G. , Abdel, Matthew P.

Mayo Clinic

JBJS Essential Surgical Techniques | June 14, 2017 | Volume: 7 | Issue: 2 | Pages: e17

10.2106/jbjs.st.16.00096 | PMID 30233952 Get It